XTL Biopharmaceuticals Effectuates ADR Ratio Change
HERZLIYA, Israel, October 4, 2012 /PRNewswire/ –
XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the “Company”), a
biopharmaceutical development company, announced today that following the announcement
from September 24, 2012, its American Depositary Receipts (“ADRs”) to ordinary shares
ratio has changed today to 1:20 (1 ADR represents 20 ordinary shares). Please note that
the ticker Symbol will temporarily change to XTLBD for 20 trading days beginning October
4th, after which it will revert back to XTLBY.
For additional information about the ADR ratio change, please contact Ms. Agness
Moskovits of Bank of New York at: (212) 815 8223.
About XTL Biopharmaceuticals,Ltd. (“XTL”)
XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition,
development, and commercialization of pharmaceutical products for the treatment of
clinical unmet needs. XTL is focused on late stage clinical development of drugs for the
treatment of multiple myeloma, schizophrenia, and hepatitis C.
XTL’s lead drug candidate, rHuEPO, for the treatment of multiple myeloma blood cancer,
was granted an orphan drug designation from the FDA. rHuEPO has been approved for
marketing by the FDA and has for many years been sold for billions of dollars across the
world for the treatment of severe anemia.
XTL is a public company traded on the Tel Aviv Stock Exchange (TASE: XTL) and its ADRs
are quoted in the US on the Pink Sheets (OTC: XTLBY).
Contact: Investor Relations, XTL Biopharmaceuticals Ltd. Tel: +972-9-955-7080, Email: firstname.lastname@example.org
SOURCE XTL Biopharmaceuticals Ltd